Pazopanib versus sunitinib in renal cancer [2]

New England Journal of Medicine

Volumn 369, Issue 20, 2013, Pages 1969-

  Casper, Jochen ^a   Schumann Binarsch, Silke ^a   Köhne, Claus Henning ^a  

^a KLINIKUM OLDENBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PAZOPANIB; SUNITINIB; ANGIOGENESIS INHIBITOR; INDOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE;

HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LETTER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; TREATMENT OUTCOME; FEMALE; KIDNEY TUMOR; MALE; NOTE; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; PYRIMIDINES; PYRROLES; SULFONAMIDES;

EID: 84887446910     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1311795     Document Type: Letter

References (4)

1. GlaxoSmithKline. Result summary for 108844 (http://www.gsk- clinicalstudyregister.com/result-detail.jsp?protocolId=108844&studyId= A1C548E6-186D-405F-B1D6-853A51D9376B&compound=pazopanib).
2. ICH harmonized tripartite guideline: statistical principles for clinical trials E9, current Step 4 version. February 5, 1998 (http://www.ich.org/ fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E9/Step4/ E9-Guideline.pdf).
3. The European Agency for the Evaluation of Medicinal Products. Points to consider on switching between superiority and non-inferiority (http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003658.pdf).
4. Haute Autorité de Santé. Le projet d'avis adopte par la Commission de la transparence le 20 Mars 2013 a fait l'objet d'une audition le 26 Juin 2013 (http://www.has-sante.fr/portail/upload/docs/application/pdf/2013- 07/votrient-reeval-rein-avis3-ct12477.pdf).